SOX9 and hepatocellular carcinoma: Co-IP and PLA experiments showed that Pep-S-A1 disrupted the YAP-SOX9 interaction in HCC cells in a dose-dependent manner, while Pep-D125A had no effect (Fig. 6c; supplementary Fig. 8a, b).